Skip to main content
. 2010 Dec;62(4):588–631. doi: 10.1124/pr.110.003004

Fig. 3.

Fig. 3.

The structures of the CB1-selective antagonists/inverse agonists, rimonabant, AM251, AM281, LY320135, and taranabant and of the CB2-selective antagonists/inverse agonists SR144528 and AM630.